These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 21673660)

  • 1. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus.
    Cerullo V; Diaconu I; Kangasniemi L; Rajecki M; Escutenaire S; Koski A; Romano V; Rouvinen N; Tuuminen T; Laasonen L; Partanen K; Kauppinen S; Joensuu T; Oksanen M; Holm SL; Haavisto E; Karioja-Kallio A; Kanerva A; Pesonen S; Arstila PT; Hemminki A
    Mol Ther; 2011 Sep; 19(9):1737-46. PubMed ID: 21673660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters.
    Dhar D; Toth K; Wold WS
    Cancer Gene Ther; 2014 Apr; 21(4):171-8. PubMed ID: 24722357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo.
    Tongu M; Harashima N; Monma H; Inao T; Yamada T; Kawauchi H; Harada M
    Cancer Immunol Immunother; 2013 Feb; 62(2):383-91. PubMed ID: 22926062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell subsets in peripheral blood and tumors of patients treated with oncolytic adenoviruses.
    Taipale K; Liikanen I; Juhila J; Karioja-Kallio A; Oksanen M; Turkki R; Linder N; Lundin J; Ristimäki A; Kanerva A; Koski A; Joensuu T; Vähä-Koskela M; Hemminki A
    Mol Ther; 2015 May; 23(5):964-973. PubMed ID: 25655312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome.
    Ge Y; Domschke C; Stoiber N; Schott S; Heil J; Rom J; Blumenstein M; Thum J; Sohn C; Schneeweiss A; Beckhove P; Schuetz F
    Cancer Immunol Immunother; 2012 Mar; 61(3):353-62. PubMed ID: 21915801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1.
    Quixabeira DCA; Cervera-Carrascon V; Santos JM; Clubb JHA; Kudling TV; Basnet S; Heiniö C; Grönberg-Vähä-Koskela S; Anttila M; Havunen R; Kanerva A; Hemminki A
    Oncoimmunology; 2022; 11(1):2028960. PubMed ID: 35083096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients.
    Ghiringhelli F; Menard C; Puig PE; Ladoire S; Roux S; Martin F; Solary E; Le Cesne A; Zitvogel L; Chauffert B
    Cancer Immunol Immunother; 2007 May; 56(5):641-8. PubMed ID: 16960692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypothesis: AdAPT-001 and pseudoprogression - when seeing is not necessarily believing.
    Conley A; Larson C; Oronsky B; Stirn M; Caroen S; Reid TR
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38886116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The rationale of dose-response curves in selecting cancer drug dosing.
    Martin JH; Dimmitt S
    Br J Clin Pharmacol; 2019 Oct; 85(10):2198-2204. PubMed ID: 31077412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Dual-Armed Oncolytic Virus Shows Clinical Efficacy in Advanced Solid Cancers.
    Silva-Pilipich N; Smerdou C
    Clin Cancer Res; 2024 Sep; 30(17):3649-3651. PubMed ID: 38935348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy.
    Hemminki O; Parviainen S; Juhila J; Turkki R; Linder N; Lundin J; Kankainen M; Ristimäki A; Koski A; Liikanen I; Oksanen M; Nettelbeck DM; Kairemo K; Partanen K; Joensuu T; Kanerva A; Hemminki A
    Oncotarget; 2015 Feb; 6(6):4467-81. PubMed ID: 25714011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.
    Liikanen I; Ahtiainen L; Hirvinen ML; Bramante S; Cerullo V; Nokisalmi P; Hemminki O; Diaconu I; Pesonen S; Koski A; Kangasniemi L; Pesonen SK; Oksanen M; Laasonen L; Partanen K; Joensuu T; Zhao F; Kanerva A; Hemminki A
    Mol Ther; 2013 Jun; 21(6):1212-23. PubMed ID: 23546299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a randomized phase I gene therapy clinical trial of nononcolytic fowlpox viruses encoding T cell costimulatory molecules.
    Kaufman HL; Kim DW; Kim-Schulze S; DeRaffele G; Jagoda MC; Broucek JR; Zloza A
    Hum Gene Ther; 2014 May; 25(5):452-60. PubMed ID: 24484178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus.
    Kanerva A; Nokisalmi P; Diaconu I; Koski A; Cerullo V; Liikanen I; Tähtinen S; Oksanen M; Heiskanen R; Pesonen S; Joensuu T; Alanko T; Partanen K; Laasonen L; Kairemo K; Pesonen S; Kangasniemi L; Hemminki A
    Clin Cancer Res; 2013 May; 19(10):2734-44. PubMed ID: 23493351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results.
    Packiam VT; Lamm DL; Barocas DA; Trainer A; Fand B; Davis RL; Clark W; Kroeger M; Dumbadze I; Chamie K; Kader AK; Curran D; Gutheil J; Kuan A; Yeung AW; Steinberg GD
    Urol Oncol; 2018 Oct; 36(10):440-447. PubMed ID: 28755959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The investigation of oncolytic viruses in the field of cancer therapy.
    Yuan Z; Zhang Y; Wang X; Wang X; Ren S; He X; Su J; Zheng A; Guo S; Chen Y; Deng S; Wu X; Li M; Du F; Zhao Y; Shen J; Wang Z; Xiao Z
    Front Oncol; 2024; 14():1423143. PubMed ID: 39055561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translation of oncolytic viruses in sarcoma.
    Robinson SI; Rochell RE; Penza V; Naik S
    Mol Ther Oncol; 2024 Sep; 32(3):200822. PubMed ID: 39040851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic Adenovirus for the Targeting of Paclitaxel-Resistant Breast Cancer Stem Cells.
    Robert S; Roman Ortiz NI; LaRocca CJ; Ostrander JH; Davydova J
    Viruses; 2024 Apr; 16(4):. PubMed ID: 38675909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide.
    Toulmonde M; Guegan JP; Spalato-Ceruso M; Peyraud F; Kind M; Vanhersecke L; Le Loarer F; Perret R; Cantarel C; Bellera C; Bessede A; Italiano A
    Mol Cancer; 2024 Feb; 23(1):38. PubMed ID: 38378555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticancer Activity of Measles-Mumps-Rubella MMR Vaccine Viruses against Glioblastoma.
    Khalid Z; Coco S; Ullah N; Pulliero A; Cortese K; Varesano S; Orsi A; Izzotti A
    Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.